These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 7817812

  • 1. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.
    Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ.
    J Bone Miner Res; 1994 Oct; 9(10):1643-9. PubMed ID: 7817812
    [Abstract] [Full Text] [Related]

  • 2. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study.
    Seibel MJ, Woitge H, Scheidt-Nave C, Leidig-Bruckner G, Duncan A, Nicol P, Ziegler R, Robins SP.
    J Bone Miner Res; 1994 Sep; 9(9):1433-40. PubMed ID: 7817828
    [Abstract] [Full Text] [Related]

  • 3. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
    DeLaurier A, Jackson B, Pfeiffer D, Ingham K, Horton MA, Price JS.
    Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
    [Abstract] [Full Text] [Related]

  • 4. [Urinary excretion of free and total deoxypyridinoline during secondary hyperparathyroidism in the elderly. Comparison of chromatographic (HPLC) and immunoenzymatic (Pyrilinks-D) methods].
    Meddah B, Brazier M, Kamel S, Maamer M, Samson L, Desmet G, Sebert JL.
    Ann Biol Clin (Paris); 1996 Aug; 54(10-11):353-8. PubMed ID: 9092303
    [Abstract] [Full Text] [Related]

  • 5. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
    Garnero P, Gineyts E, Riou JP, Delmas PD.
    J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
    [Abstract] [Full Text] [Related]

  • 6. Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion.
    Del Campo MT, González-Casaus ML, Aguado P, Bernad M, Carrera F, Martínez ME.
    Osteoporos Int; 1999 Sep; 9(5):449-54. PubMed ID: 10550465
    [Abstract] [Full Text] [Related]

  • 7. Automated and manual assays for urinary crosslinks of collagen: which assay to use?
    Seibel MJ, Woitge HW, Farahmand I, Oberwittler H, Ziegler R.
    Exp Clin Endocrinol Diabetes; 1998 Sep; 106(2):143-8. PubMed ID: 9628247
    [Abstract] [Full Text] [Related]

  • 8. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes.
    Fassbender WJ, Gödde M, Brandenburg VM, Usadel KH, Stumpf UC.
    Adv Med Sci; 2009 Sep; 54(1):1-6. PubMed ID: 19482729
    [Abstract] [Full Text] [Related]

  • 9. Immunoassay for urinary pyridinoline: the new marker of bone resorption.
    Seyedin SM, Kung VT, Daniloff YN, Hesley RP, Gomez B, Nielsen LA, Rosen HN, Zuk RF.
    J Bone Miner Res; 1993 May; 8(5):635-41. PubMed ID: 8511991
    [Abstract] [Full Text] [Related]

  • 10. Markers of bone resorption--measurement in serum, plasma or urine?
    Huber F, Traber L, Roth HJ, Heckel V, Schmidt-Gayk H.
    Clin Lab; 2003 May; 49(5-6):203-7. PubMed ID: 15285175
    [Abstract] [Full Text] [Related]

  • 11. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease.
    Delmas PD, Gineyts E, Bertholin A, Garnero P, Marchand F.
    J Bone Miner Res; 1993 May; 8(5):643-8. PubMed ID: 8511992
    [Abstract] [Full Text] [Related]

  • 12. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
    Kitatani K, Nakatsuka K, Naka H, Miki T, Morii H, Nishizawa Y.
    J Bone Miner Metab; 2003 May; 21(4):217-24. PubMed ID: 12811626
    [Abstract] [Full Text] [Related]

  • 13. Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis.
    Nur E, Mairuhu W, Biemond BJ, van Zanten AP, Schnog JJ, Brandjes DP, Otten HM, CURAMA study group.
    Am J Hematol; 2010 Nov; 85(11):902-4. PubMed ID: 20882525
    [Abstract] [Full Text] [Related]

  • 14. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.
    Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, Lindsay R.
    J Bone Miner Res; 1993 Jul; 8(7):881-9. PubMed ID: 8352070
    [Abstract] [Full Text] [Related]

  • 15. Urinary gamma-glutamyltransferase (GGT) as a potential marker of bone resorption.
    Asaba Y, Hiramatsu K, Matsui Y, Harada A, Nimura Y, Katagiri N, Kobayashi T, Takewaka T, Ito M, Niida S, Ikeda K.
    Bone; 2006 Dec; 39(6):1276-82. PubMed ID: 16942925
    [Abstract] [Full Text] [Related]

  • 16. Effect of pamidronate on excretion of pyridinium crosslinks of collagen after total hip arthroplasty.
    Wilkinson JM, Jackson B, Eastell R.
    Calcif Tissue Int; 2003 Oct; 73(4):326-31. PubMed ID: 12874697
    [Abstract] [Full Text] [Related]

  • 17. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
    Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Bréart G, Meunier PJ, Delmas PD.
    J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
    [Abstract] [Full Text] [Related]

  • 18. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
    Randall AG, Kent GN, Garcia-Webb P, Bhagat CI, Pearce DJ, Gutteridge DH, Prince RL, Stewart G, Stuckey B, Will RK, Retallack RW, Price RI, Ward L.
    J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
    [Abstract] [Full Text] [Related]

  • 19. Reference value for urinary deoxypyridinoline as a specific marker for measuring bone resorption in Thais.
    Pidetcha P, Intramanee S, Patrakarn K, Leelahakul P, Fongsupa S.
    J Med Assoc Thai; 1999 Nov; 82(11):1136-41. PubMed ID: 10659549
    [Abstract] [Full Text] [Related]

  • 20. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
    Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD.
    J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.